Autolus Therapeutics plc AUTL
1.19 USD -0.05 (-3.64%)
At closeNov 13, 2026, 4:00 AM EST
1.20 +0.01 +0.83%
Pre-market · Nov 13, 4:00 AM ET
1.17 Day range 1.24
1.12 52-week range 2.58
- YTD
- -40.20%
- 1 year
- -12.50%
News
benzinga.com Autolus Therapeutics Presents Longer-Term Follow Up Data From Ongoing CARLYSLE Phase 1 Trial; Data Show Clinically Significant Improvements In SLEDAI-2K Scores And Achievement Of DORIS In Most Patients Despite Severe Disease Activity At Baseline Fonger-term follow up data from the ongoing CARLYSLE trial, a Phase 1 dose confirmation clinical trial of obe-cel in severe refractory systemic lupus erythematosus (srSLE), was presented today during…
globenewswire.com Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026 Data show clinically significant improvements in SLEDAI-2K scores and achievement of DORIS in most patients, despite severe disease activity at baseline In 15 patients evaluable for safety, obe-cel…
seekingalpha.com Autolus Therapeutics plc (AUTL) Q3 2026 Earnings Call Transcript Autolus Therapeutics plc (AUTL) Q3 2026 Earnings Call Transcript
marketbeat.com Autolus Therapeutics Q3 Earnings Call Highlights Autolus Therapeutics NASDAQ: AUTL raised its full-year AUCATZYL sales outlook after third-quarter revenue nearly doubled from a year earlier, as the company reported improved manufacturing margins…
benzinga.com Autolus Therapeutics Q3 2026 Earnings Call Transcript Autolus Therapeutics (NASDAQ:AUTL) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Autolus Therapeutics FY2026 AUCATZYL net product revenue expected to be more than $150.000M Autolus Therapeutics (NASDAQ:AUTL) FY2026 AUCATZYL net product revenue expected to be more than $150.000M.
benzinga.com Autolus Therapeutics Q3 EPS $(0.21) Misses $(0.18) Estimate, Sales $41.238M Beat $39.537M Estimate Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.18) by 16.67 percent. This is a 30 percent increase over losses of…
globenewswire.com Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $41.2 million, an increase of 95% year-over-year; now expects full-year 2026 AUCATZYL net product revenue to be at…
globenewswire.com Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference LONDON and GAITHERSBURG, Md., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…- benzinga.com Autolus Therapeutics To Present Clinical Update Abstracts At American Society of Hematology Meeting, December 12-15 Abstract 4498 – Oral PresentationTitle: What to expect during the first 3 months post obecabtagene autoleucel (obe-cel) infusion in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia…
benzinga.com HC Wainwright & Co. Assumes Autolus Therapeutics at Buy, Announces Price Target of $10 HC Wainwright & Co. analyst Douglas Tsao assumes Autolus Therapeutics (NASDAQ:AUTL) with a Buy rating and announces Price Target of $10.